"I have never heard of the FDA doing something like this, but again it was clearly stated it came from OWS. Sometimes NP gets the initials wrong, perhaps he meant OWS, perhaps OWS has made this their new protocol, but CYDY is not part of OWS, the other company is."

Both could be true. Remember, Dr. Woodcock was head of therapeutics at OWS and now acting head of FDA. So it's possible and not mutually exclusive.

Read More: https://investorshangout.com/post/view?id=603...z6lA3H9KD0